```
=> d his ful

     (FILE 'HOME' ENTERED AT 12:57:36 ON 27 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 12:57:42 ON 27 SEP 2005
L1              STRUCTURE UPLOADED
L2              STRUCTURE UPLOADED
L3            2 SEA SSS SAM L2
L4           34 SEA SSS FUL L2
L5           34 SEA SUB=L4 SSS FUL L1

     FILE 'HCAPLUS, CASREACT, USPATFULL, TOXCENTER, BEILSTEIN' ENTERED AT
     12:59:52 ON 27 SEP 2005
L6           16 SEA PLU=ON  L4
L7           16 SEA PLU=ON  L5
L8           16 SEA PLU=ON  L6 OR L7
L9           13 DUP REM L8 (3 DUPLICATES REMOVED)
                    ANSWERS '1-12' FROM FILE HCAPLUS
                    ANSWER '13' FROM FILE USPATFULL

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 13:00:47 ON 27 SEP 2005
L10          13 SEA PLU=ON  L9
L11          11 SEA PLU=ON  L10 AND (PD<20030116 OR PRD<20030116)
L*** DEL      0 L11 AND PRD=01182002
L12           2 SEA PLU=ON  L11 AND PRD=20020118
L13           9 SEA PLU=ON  L11 NOT L12
                D L13 1-9 IBIB HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   26 SEP 2005  HIGHEST RN 863963-04-6
     DICTIONARY FILE UPDATES:  26 SEP 2005  HIGHEST RN 863963-04-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html
```

FILE HCAPLUS
FILE COVERS 1907 - 27 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 26 Sep 2005 (20050926/ED)

FILE CASREACT
FILE CONTENT:1840 - 25 Sep 2005 VOL 143 ISS 13

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Sep 2005 (20050922/PD)
FILE LAST UPDATED: 22 Sep 2005 (20050922/ED)
CA INDEXING IS CURRENT THROUGH 22 Sep 2005 (20050922/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Sep 2005 (20050922/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005

FILE TOXCENTER
FILE COVERS 1907 TO 27 Sep 2005 (20050927/ED)

FILE BEILSTEIN
FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005
FILE COVERS 1771 TO 2005.

=> d que sta
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 STR



Structure attributes must be viewed using STN Express query preparation.
L4 34 SEA FILE=REGISTRY SSS FUL L2
L5 34 SEA FILE=REGISTRY SUB=L4 SSS FUL L1
L6 16 SEA L4
L7 16 SEA L5
L8 16 SEA L6 OR L7

L9	13	DUP REM L8 (3 DUPLICATES REMOVED)
L10	13	SEA L9
L11	11	SEA L10 AND (PD<20030116 OR PRD<20030116)
L12	2	SEA L11 AND PRD=20020118
L13	9	SEA L11 NOT L12

```
=> d his ful

     (FILE 'HOME' ENTERED AT 12:26:17 ON 27 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 12:26:39 ON 27 SEP 2005
L1             STRUCTURE UPLOADED
               D QUE
L2           1 SEA SSS SAM L1
L3          15 SEA SSS FUL L1

     FILE 'HCAPLUS, USPATFULL, TOXCENTER, BEILSTEIN' ENTERED AT 12:28:21 ON 27
     SEP 2005
L4           6 SEA PLU=ON  L3
L5           6 DUP REM L4 (0 DUPLICATES REMOVED)
                   ANSWERS '1-5' FROM FILE HCAPLUS
                   ANSWER '6' FROM FILE USPATFULL

     FILE 'REGISTRY' ENTERED AT 12:28:49 ON 27 SEP 2005
L6             SEL PLU=ON  L3 1- CHEM :      16 TERMS

     FILE 'HCAPLUS, USPATFULL, TOXCENTER, BEILSTEIN' ENTERED AT 12:28:51 ON 27
     SEP 2005
L7           5 SEA PLU=ON  L6
L8           5 DUP REM L7 (0 DUPLICATES REMOVED)
                   ANSWERS '1-5' FROM FILE HCAPLUS
L9           6 SEA PLU=ON  L5 OR L8
               E L5
L10          6 DUP REM L9 (0 DUPLICATES REMOVED)
                   ANSWERS '1-5' FROM FILE HCAPLUS
                   ANSWER '6' FROM FILE USPATFULL
               D L10 1-6 IBIB HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   26 SEP 2005  HIGHEST RN 863963-04-6
     DICTIONARY FILE UPDATES:  26 SEP 2005  HIGHEST RN 863963-04-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
```

to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

FILE HCAPLUS
FILE COVERS 1907 - 27 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 26 Sep 2005 (20050926/ED)

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Sep 2005 (20050922/PD)
FILE LAST UPDATED: 22 Sep 2005 (20050922/ED)
CA INDEXING IS CURRENT THROUGH 22 Sep 2005 (20050922/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Sep 2005 (20050922/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005

FILE TOXCENTER
FILE COVERS 1907 TO 27 Sep 2005 (20050927/ED)

FILE BEILSTEIN
FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005
FILE COVERS 1771 TO 2005.

=> d que sta
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 15 SEA FILE=REGISTRY SSS FUL L1
L4 6 SEA L3
L5 6 DUP REM L4 (0 DUPLICATES REMOVED)
L6 SEL PLU=ON L3 1- CHEM : 16 TERMS
L7 5 SEA L6
L8 5 DUP REM L7 (0 DUPLICATES REMOVED)
L9 6 SEA L5 OR L8
L10 6 DUP REM L9 (0 DUPLICATES REMOVED)

=> d l10 1-6 ibib hitstr

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:445915 HCAPLUS Full-text
DOCUMENT NUMBER: 141:116450
TITLE: Structural Determinants of RXPA380, a Potent and Highly Selective Inhibitor of the Angiotensin-Converting Enzyme C-Domain
AUTHOR(S): Georgiadis, Dimitris; Cuniasse, Philippe; Cotton, Joeel; Yiotakis, Athanasios; Dive, Vincent
CORPORATE SOURCE: Departement d'Ingenerie et d'Etudes des Proteines, CEA, Gif sur Yvette, 91191, Fr.
SOURCE: Biochemistry (2004), 43(25), 8048-8054
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **564479-79-4P 564479-80-7P 564479-81-8P**
564479-83-0P 564479-84-1P 724750-81-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relationship of RXPA380 analogs, as potent and highly selective inhibitors of angiotensin-converting enzyme C-domain)
RN 564479-79-4 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-80-7 HCAPLUS
CN L-Alanine, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-81-8 HCAPLUS
CN L-Proline, 1-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-83-0 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-84-1 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-3-phenyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724750-81-6 HCAPLUS
CN L-Lysine, N2-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-6-imino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1121942 HCAPLUS Full-text
DOCUMENT NUMBER: 142:169619
TITLE: Selective Angiotensin-Converting Enzyme C-Domain Inhibition Is Sufficient to Prevent Angiotensin I-Induced Vasoconstriction
AUTHOR(S): van Esch, Joep H. M.; Tom, Beril; Dive, Vincent; Batenburg, Wendy W.; Georgiadis, Dimitris; Yiotakis, Athanasios; van Gool, Jeanette M. G.; de Bruijn, Rene J. A.; de Vries, Rene; Danser, A. H. Jan
CORPORATE SOURCE: Department of Pharmacology and Internal Medicine, Erasmus MC, Rotterdam, Neth.
SOURCE: Hypertension (2004), Volume Date 2005, 45(1), 120-125
CODEN: HPRTDN; ISSN: 0194-911X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **564479-79-4, RXPA 380**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction)
RN 564479-79-4 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:573238 HCAPLUS Full-text
DOCUMENT NUMBER: 139:117690
TITLE: Preparation of phosphinic pseudo-peptide derivatives which selectively inhibit the C-terminal active site of angiotensin-converting enzyme (ACE)

INVENTOR(S): Cotton, Joel; Georgiadis, Dimitri; Dive, Vincent
PATENT ASSIGNEE(S): Commissariat A L'energie Atomique, Fr.
SOURCE: Fr. Demande, 48 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2834989	A1	20030725	FR 2002-599	20020118
FR 2834989	B1	20050520		
CA 2473047	AA	20030731	CA 2003-2473047	20030116
WO 2003062247	A2	20030731	WO 2003-FR129	20030116
WO 2003062247	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1468003	A2	20041020	EP 2003-717341	20030116
EP 1468003	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522420	T2	20050728	JP 2003-562124	20030116
US 2005070505	A1	20050331	US 2004-500891	20040707

PRIORITY APPLN. INFO.: FR 2002-599 A 20020118
WO 2003-FR129 W 20030116

OTHER SOURCE(S): MARPAT 139:117690

IT **564479-79-4P 564479-80-7P 564479-81-8P**
564479-82-9P 564479-83-0P 564479-84-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphinic pseudo-peptide derivs. as inhibitors of the C-terminal active site of angiotensin-converting enzyme (ACE))

RN 564479-79-4 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-80-7 HCAPLUS
CN L-Alanine, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]

ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-81-8 HCAPLUS
CN L-Proline, 1-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-82-9 HCAPLUS
CN L-Arginine, N2-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-83-0 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-84-1 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-3-phenyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:547435 HCAPLUS Full-text
DOCUMENT NUMBER: 139:346065
TITLE: Roles of the two active sites of somatic angiotensin-converting enzyme in cleavage of angiotensin I and bradykinin
AUTHOR(S): Georgiadis, Dimitris; Beau, Fabrice; Czarny, Bertrand; Cotton, Joel; Yiotakis, Athanasios; Dive, Vincent
CORPORATE SOURCE: Department of Chemistry, Laboratory of Organic Chemistry, University of Athens, Athens, Greece
SOURCE: Circulation Research (2003), 93(2), 148-154
CODEN: CIRUAL; ISSN: 0009-7330
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **564479-79-4, RXPA 380**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(roles of two active sites of somatic angiotensin-converting enzyme in cleavage of angiotensin I and bradykinin as evaluated in mice in relation to insights from selective inhibitors)
RN 564479-79-4 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:612686 HCAPLUS Full-text
DOCUMENT NUMBER: 113:212686
TITLE: Peptide analogs as human immunodeficiency virus (HIV) protease inhibitors
INVENTOR(S): Hanko, Rudolf H.; Scangos, George A.; Yoo-Warren, Heeja; Ramabhadran, Triprayar V.; Paessens, Arnold; Henning, Rolf; Tamburini, Paul Perry; Hoppe, Dieter; Hansen, Jutta; Rabe, Klaus
PATENT ASSIGNEE(S): Molecular Therapeutics, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 361341	A2	19900404	EP 1989-117616		19890923
EP 361341	A3	19910703			
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
FI 8904541	A	19900329	FI 1989-4541		19890926
AU 8942308	A1	19900816	AU 1989-42308		19890926
AU 633017	B2	19930121			
DK 8904760	A	19900329	DK 1989-4760		19890927
NO 8903834	A	19900329	NO 1989-3834		19890927
ZA 8907338	A	19900725	ZA 1989-7338		19890927
JP 02191243	A2	19900727	JP 1989-253683		19890928
PRIORITY APPLN. INFO.:			US 1988-250472	A	19880928
			US 1989-386194	A	19890801

OTHER SOURCE(S): MARPAT 113:212686
IT **130371-94-7P 130371-96-9P 130371-98-1P**
130371-99-2P 130372-01-9P 130372-02-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as HIV protease inhibitor)
RN 130371-94-7 HCAPLUS
CN 2-Oxa-5,8-diaza-3-phosphanonan-9-oic acid, 7-(2-amino-2-oxoethyl)-3-[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]-6-oxo-4-(phenylmethyl)-, 1,1-dimethylethyl ester, 3-oxide (9CI) (CA INDEX NAME)



RN 130371-96-9 HCAPLUS
CN L-Isoleucine, N-[[2-[[1-[(2,4-diamino-1,4-dioxobutyl)amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 130371-98-1 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130371-99-2 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[hydroxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130372-01-9 HCAPLUS
CN L-Aspartamide, L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130372-02-0 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-seryl-L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



IT **130372-29-1P 130372-32-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HIV protease inhibitor (intermediate))
RN 130372-29-1 HCAPLUS
CN L-Isoleucine, N-[[2-[methoxy[2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

*Absolute stereochemistry.



RN 130372-32-6 HCAPLUS
CN L-Isoleucine, N-[[2-[(1-amino-2-phenylethyl)methoxyphosphinyl]cyclopentyl] carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2005:82057 USPATFULL Full-text
TITLE:	Phosphinic pseudo-peptide derivatives for the selective inhibition of the active c-terminal site of angiotensin converting enzyme (I) (ace)
INVENTOR(S):	Cotton, Joel, Orsay, FRANCE Georgiadis, Dimitri, Athens, GREECE Dive, Vincent, Palaiseau, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005070505	A1	20050331	
APPLICATION INFO.:	US 2004-500891	A1	20040707	(10)
	WO 2003-FR129		20030116	

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2002-599	20020118

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **564479-79-4P 564479-80-7P 564479-81-8P**
564479-82-9P 564479-83-0P 564479-84-1P
(preparation of phosphinic pseudo-peptide derivs. as inhibitors of the C-terminal active site of angiotensin-converting enzyme (ACE))

RN 564479-79-4 USPATFULL

CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-80-7 USPATFULL

CN L-Alanine, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-81-8 USPATFULL

CN L-Proline, 1-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-82-9 USPATFULL

CN L-Arginine, N2-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-83-0 USPATFULL
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 564479-84-1 USPATFULL
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-3-phenyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l13 1-9 ibib hitstr

L13 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:547435 HCAPLUS
DOCUMENT NUMBER: 139:346065
TITLE: Roles of the two active sites of somatic angiotensin-converting enzyme in cleavage of angiotensin I and bradykinin
AUTHOR(S): Georgiadis, Dimitris; Beau, Fabrice; Czarny, Bertrand; Cotton, Joel; Yiotakis, Athanasios; Dive, Vincent
CORPORATE SOURCE: Department of Chemistry, Laboratory of Organic Chemistry, University of Athens, Athens, Greece
SOURCE: Circulation Research (**2003**), 93(2), 148-154
CODEN: CIRUAL; ISSN: 0009-7330
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **564479-79-4**, RXPA 380
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(roles of two active sites of somatic angiotensin-converting enzyme in cleavage of angiotensin I and bradykinin as evaluated in mice in relation to insights from selective inhibitors)
RN 564479-79-4 HCAPLUS
CN L-Tryptophan, N-[[2-[hydroxy[(1R)-2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:615126 HCAPLUS
DOCUMENT NUMBER: 135:358118
TITLE: Synthesis of phosphinic alanyl-proline surrogates Alaψ(PO2R-CH)Pro as potential inhibitors of the human cyclophilin hCyp-18
AUTHOR(S): Demange, Luc; Dugave, Christophe
CORPORATE SOURCE: Departement d'Ingenierie et d'Etudes des Proteines (DIEP), CEA/Saclay, Gif-sur-Yvette, Fr.
SOURCE: Tetrahedron Letters (**2001**), 42(36), 6295-6297
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:358118

IT **372987-88-7P 372987-90-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of phosphinic alanyl-proline surrogates as potential inhibitors of the human cyclophilin hCyp-18)

RN 372987-88-7 HCAPLUS

CN Benzeneacetic acid, 4-[[(2S)-2-[[[2-[[1-(acetylamino)ethyl]hydroxyphosphinyl]cyclopentyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 372987-90-1 HCAPLUS

CN Benzeneacetic acid, 4-[[(2S)-2-[[[2-[[1-(acetylamino)ethyl]methoxyphosphinyl]cyclopentyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **372987-82-1P 372987-84-3P 372987-86-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and biol. activity of phosphinic alanyl-proline surrogates as potential inhibitors of the human cyclophilin hCyp-18)

RN 372987-82-1 HCAPLUS

CN Benzeneacetic acid, 4-[[(2S)-1-oxo-3-phenyl-2-[[[2-[[1-[[(phenylmethoxy)carbonyl]amino]ethyl](tricyclo[3.3.1.13,7]dec-1-yloxy)phosphinyl]cyclopentyl]carbonyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 372987-84-3 HCAPLUS
CN Benzeneacetic acid, 4-[[(2S)-2-[[[2-[(1-aminoethyl)(tricyclo[3.3.1.13,7]dec-1-yloxy)phosphinyl]cyclopentyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 372987-86-5 HCAPLUS
CN Benzeneacetic acid, 4-[[(2S)-2-[[[2-[[1-(acetylamino)ethyl](tricyclo[3.3.1.13,7]dec-1-yloxy)phosphinyl]cyclopentyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:792014 HCAPLUS
DOCUMENT NUMBER: 128:60440
TITLE: Comparison of different immunoenzymic methods for the determination of the fine specificity and affinity constants of polyclonal antibodies against pseudopeptide haptens
AUTHOR(S): Fournout, S.; Jouin, P.; Pau, B.; Hanin, V.
CORPORATE SOURCE: Immunoanalyse et Innovation en Biologie Clinique, CNRS UMR 9921, Faculte de Pharmacie, Montpellier, Fr.
SOURCE: Immunological Investigations (**1997**), 26(5-7), 549-559
CODEN: IMINEJ; ISSN: 0882-0139
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **189227-54-1**
RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunoenzymic methods comparison for determination of fine specificity and affinity consts. of polyclonal antibodies against pseudopeptide haptens)
RN 189227-54-1 HCAPLUS
CN L-Cysteine, N-acetyl-L-seryl-L-alanyl-L-alanyl-2-[(1-amino-2-phenylethyl)hydroxyphosphinyl]cyclopentanecarbonyl-L-valyl-L-valyl-6-aminohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:215813 HCAPLUS
DOCUMENT NUMBER: 126:303001
TITLE: Development and Standardization of an Immuno-Quantified Solid Phase Assay for HIV-1 Aspartyl Protease Activity and Its Application to the Evaluation of Inhibitors
AUTHOR(S): Fournout, S.; Roquet, F.; Salhi, S. L.; Seyer, R.; Valverde, V.; Masson, J. M.; Jouin, P.; Pau, B.; Nicolas, M.; Hanin, V.
CORPORATE SOURCE: Laboratoire d'Immunoanalyse et Innovation en Biologie Clinique, Faculte de Pharmacie, Montpellier, 34060, Fr.
SOURCE: Analytical Chemistry (**1997**), 69(9), 1746-1752
CODEN: ANCHAM; ISSN: 0003-2700
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **189227-54-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
(development and standardization of an immuno-quantified solid phase assay for HIV-1 aspartyl protease activity and its application to the evaluation of inhibitors)

RN 189227-54-1 HCAPLUS

CN L-Cysteine, N-acetyl-L-seryl-L-alanyl-L-alanyl-2-[(1-amino-2-phenylethyl)hydroxyphosphinyl]cyclopentanecarbonyl-L-valyl-L-valyl-6-aminohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:76343 HCAPLUS

DOCUMENT NUMBER: 116:76343

TITLE: Method for treating fungal infection with an aspartic acid proteinase inhibitor

INVENTOR(S): Dreyer, Geoffrey Bainbridge; Frey, Carrie Lynn; Koltin, Yigal

PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9115121	A1	19911017	WO 1991-US2145		19910328	<--
W: AU, CA, JP, KR, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE						
AU 9176739	A1	19911030	AU 1991-76739		19910328	<--
PRIORITY APPLN. INFO.:			US 1990-502149	A	19900330	<--
			WO 1991-US2145	A	19910328	<--

OTHER SOURCE(S): MARPAT 116:76343
IT **126333-35-5**
RL: BIOL (Biological study)
(antifungal agent)
RN 126333-35-5 HCAPLUS
CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:240604 HCAPLUS
DOCUMENT NUMBER: 114:240604
TITLE: Preparation of retroviral protease binding peptides
INVENTOR(S): Dreyer, Geoffrey Bainbridge; Huffman, William Francis; Meek, Thomas Downing; Metcalf, Brian Walter; Moore, Michael Lee
PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9000399	A1	19900125	WO 1989-US2972	19890707 <--
W: AU, DK, FI, HU, JP, KR, NO				
AU 8939644	A1	19900205	AU 1989-39644	19890707 <--
ZA 8905174	A	19900328	ZA 1989-5174	19890707 <--
JP 03505875	T2	19911219	JP 1989-507665	19890707 <--
HU 58764	A2	19920330	HU 1989-4124	19890707 <--
DK 9100026	A	19910306	DK 1991-26	19910107 <--
NO 9100053	A	19910307	NO 1991-53	19910107 <--
NO 9200318	A	19910307	NO 1992-318	19920123 <--
NO 9200319	A	19910307	NO 1992-319	19920123 <--
PRIORITY APPLN. INFO.:			US 1988-216178 A	19880708 <--
			US 1989-321937 A	19890310 <--
			US 1989-374326 A	19890629 <--
			WO 1989-US2972 A	19890707 <--
			NO 1991-53 A1	19910107 <--

OTHER SOURCE(S): MARPAT 114:240604

IT **126333-35-5P 128210-19-5P 128234-78-6P 128299-07-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiviral agent)

RN 126333-35-5 HCAPLUS

CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128210-19-5 HCAPLUS

CN L-Valine, N-[N-[[2-[[1-[[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-seryl]-L-alanyl]-L-alanyl]amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 128234-78-6 HCAPLUS
CN L-Valine, N-[N-[[2-[[1-[[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-seryl]-L-alanyl]-L-alanyl]amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 128299-07-0 HCAPLUS
CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HBr

IT **128211-25-6P 128211-26-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antivirals)
RN 128211-25-6 HCAPLUS
CN L-Valine, N-[N-[[2-[methoxy[2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 128211-26-7 HCAPLUS
CN L-Valine, N-[N-[[2-[(1-amino-2-phenylethyl)methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:612686 HCAPLUS
DOCUMENT NUMBER: 113:212686
TITLE: Peptide analogs as human immunodeficiency virus (HIV) protease inhibitors
INVENTOR(S): Hanko, Rudolf H.; Scangos, George A.; Yoo-Warren, Heeja; Ramabhadran, Triprayar V.; Paessens, Arnold; Henning, Rolf; Tamburini, Paul Perry; Hoppe, Dieter; Hansen, Jutta; Rabe, Klaus
PATENT ASSIGNEE(S): Molecular Therapeutics, Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 361341	A2	19900404	EP 1989-117616	19890923 <--
EP 361341	A3	19910703		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8904541	A	19900329	FI 1989-4541	19890926 <--
AU 8942308	A1	19900816	AU 1989-42308	19890926 <--
AU 633017	B2	19930121		
DK 8904760	A	19900329	DK 1989-4760	19890927 <--
NO 8903834	A	19900329	NO 1989-3834	19890927 <--
ZA 8907338	A	19900725	ZA 1989-7338	19890927 <--
JP 02191243	A2	19900727	JP 1989-253683	19890928 <--
PRIORITY APPLN. INFO.:			US 1988-250472 A	19880928 <--
			US 1989-386194 A	19890801 <--

OTHER SOURCE(S): MARPAT 113:212686
IT **130371-93-6P 130371-94-7P 130371-95-8P**
130371-96-9P 130371-97-0P 130371-98-1P
130371-99-2P 130372-00-8P 130372-01-9P
130372-02-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as HIV protease inhibitor)
RN 130371-93-6 HCAPLUS
CN Carbamic acid, [3-amino-1-[[[1-[methoxy[2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]amino]carbonyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 130371-94-7 HCAPLUS
CN 2-Oxa-5,8-diaza-3-phosphanonan-9-oic acid, 7-(2-amino-2-oxoethyl)-3-[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]-6-oxo-4-(phenylmethyl)-, 1,1-dimethylethyl ester, 3-oxide (9CI) (CA INDEX NAME)



RN 130371-95-8 HCAPLUS
CN Phosphinic acid, [1-[(2,4-diamino-1,4-dioxobutyl)amino]-2-phenylethyl][2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]cyclopentyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 130371-96-9 HCAPLUS
CN L-Isoleucine, N-[[2-[[1-[(2,4-diamino-1,4-dioxobutyl)amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 130371-97-0 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[methoxy[2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]c

arbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130371-98-1 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130371-99-2 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[hydroxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130372-00-8 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N1-[1-[hydroxy[2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130372-01-9 HCAPLUS
CN L-Aspartamide, L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



RN 130372-02-0 HCAPLUS
CN L-Aspartamide, N-[(1,1-dimethylethoxy)carbonyl]-L-seryl-L-phenylalanyl-N1-[1-[methoxy[2-[[[1-(methoxycarbonyl)-2-methylbutyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



IT **130372-29-1P 130372-30-4P 130372-31-5P**
130372-32-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as HIV protease inhibitor (intermediate))
RN 130372-29-1 HCAPLUS
CN L-Isoleucine, N-[[2-[methoxy[2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 130372-30-4 HCAPLUS
CN Carbamic acid, [1-[methoxy[2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]cyclopentyl]phosphinyl]-2-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 130372-31-5 HCAPLUS
CN Phosphinic acid, (1-amino-2-phenylethyl)[2-[[[2-methyl-1-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]cyclopentyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 130372-32-6 HCAPLUS
CN L-Isoleucine, N-[[2-[(1-amino-2-phenylethyl)methoxyphosphinyl]cyclopentyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:553045 HCAPLUS
DOCUMENT NUMBER: 113:153045
TITLE: Preparation of retroviral protease-inhibiting peptides and pharmaceutical compositions containing them
INVENTOR(S): Dreyer, Geoffrey Bainbridge; Huffman, William Francis; Meek, Thomas Dowing; Metcalf, Brian Walter; Moore, Michael Lee
PATENT ASSIGNEE(S): SmithKline Beckman Corp., USA
SOURCE: Eur. Pat. Appl., 118 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 352000	A2	19900124	EP 1989-306995	19890710 <--
EP 352000	A3	19910717		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8905174	A	19900328	ZA 1989-5174	19890707 <--
CN 1039596	A	19900214	CN 1989-104699	19890708 <--
PRIORITY APPLN. INFO.:			US 1988-216178 A	19880708 <--
			US 1989-321937 A	19890310 <--

OTHER SOURCE(S): MARPAT 113:153045
IT **128211-25-6P 128211-26-7P 128234-86-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of protease inhibiting peptides)
RN 128211-25-6 HCAPLUS
CN L-Valine, N-[N-[[2-[methoxy[2-phenyl-1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 128211-26-7 HCAPLUS
CN L-Valine, N-[N-[[2-[(1-amino-2-phenylethyl)methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128234-86-6 HCAPLUS
CN L-Valine, N-[N-[[2-[[1-[[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-O-(trimethylsilyl)-L-seryl]-L-alanyl]-L-alanyl]amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **126333-35-5P 128210-19-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as retroviral protease inhibitor)
RN 126333-35-5 HCAPLUS
CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128210-19-5 HCAPLUS
CN L-Valine, N-[N-[[2-[[1-[[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-seryl]-L-alanyl]-L-alanyl]amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbon

yl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **128234-78-6P 128299-07-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as viral protease inhibitor)

RN 128234-78-6 HCAPLUS

CN L-Valine, N-[N-[[2-[[1-[[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-seryl]-L-alanyl]-L-alanyl]amino]-2-phenylethyl]methoxyphosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 128299-07-0 HCAPLUS

CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-

alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HBr

L13 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:400142 HCAPLUS
DOCUMENT NUMBER: 113:142
TITLE: Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analog inhibitors
AUTHOR(S): Dreyer, Geoffrey B.; Metcalf, Brian W.; Tomaszek, Thaddeus A., Jr.; Carr, Thomas J.; Chandler, Arthur C., III; Hyland, Lawrence; Fakhoury, Stephen A.; Magaard, Victoria W.; Moore, Michael L.; et al.
CORPORATE SOURCE: Dep. Med. Chem., Smith Kline and French Lab., King of Prussia, PA, 19406-0939, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1989**), 86(24), 9752-6
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **126333-35-5DP**, isomers
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and HIV-1 protease inhibiting activity of)
RN 126333-35-5 HCAPLUS
CN L-Valine, N-[N-[[2-[hydroxy[2-phenyl-1-[[N-(N-L-seryl-L-alanyl)-L-

alanyl]amino]ethyl]phosphinyl]cyclopentyl]carbonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.